Amgen to start chronic kidney disease study
NEW YORK (Reuters) – U.S. biotechnology company Amgen Inc.
said on Sunday it will start a large-scale drug study of its
Sensipar/Mimpara drugs in chronic kidney disease patients.
The late-stage, Phase 3, study will enroll 3,800 patients
around the world, Amgen said.
Amgen said enrollment in the study is expected to begin in
the second half of 2006.